Patients undergoing partial pancreatectomy may develop type 3c diabetes mellitus (T3cDM) after the procedure, with risk factors including type of resection, volume of pancreas resected and preoperative glycaemic control, a study reports.
Real-world data from the PCORnet* Bariatric Study suggest that Roux-en-Y gastric bypass (RYGB) may be preferable to sleeve gastrectomy (SG) in inducing and maintaining type 2 diabetes (T2DM) remission.
Use of combination therapy with sodium–glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for treating type 2 diabetes mellitus (T2DM) or obese patients yields favourable effects on glycaemic control, body weight and systolic blood pressure (SBP) without increasing the incidence of adverse events, according to the results of a meta-analysis.
Treatment with metformin yields reductions in total and low-density lipoprotein cholesterol levels in individuals without diabetes, even providing an additional triglyceride-lowering effect among those with polycystic ovary syndrome (PCOS), according to the results of a meta-analysis.
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.